The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the ... systolic blood pressure in a phase 3 chronic kidney disease trial.

Additionally, Novo Nordisk is exploring expanded indications for its existing products. One notable development is the recent FDA approval of Ozempic for chronic kidney disease (CKD) patients with ...

Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...

head of development at Novo Nordisk, noted that hypertension is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease, and premature death. “With its expected ...

Novo Nordisk alleges Singaporean biotech KBP ... regional rights to roxadustat After ditching FibroGen’s chronic kidney disease drug roxadustat in the U.S., AstraZeneca has decided to take ...